The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function

Cellular Immunology

Volumn 251, Issue 2, 2008, Pages 131-136

  Ramasamy, Rajesh ^a,b   Tong, Chih Kong ^a   Seow, Heng Fong ^a   Vidyadaran, Sharmili ^a   Dazzi, Francesco ^b  

^a Faculty of Science   (Malaysia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immunosuppression; Mesenchymal stem cells; T cells

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGENIC AGENT; PHYTOHEMAGGLUTININ;

ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; FLUORESCEINS; HUMANS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; SUCCINIMIDES; THYMIDINE;

EID: 47249117877     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.04.009     Document Type: Article

References (30)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
2. Horwitz E.E. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy 7 (2005) 393-395
3. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
4. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., Ross J., Haug J., Johnson T., Feng J.Q., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
5. Dazzi F., Ramasamy R., Glennie S., Jones S., and Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 20 (2005) 161-171
6. Rzhaninova A.A., Gornostaeva S.N., and Goldshtein D.V. Isolation and phenotypical characterization of mesenchymal stem cells from human fetal thymus. Bull. Exp. Biol. Med. 139 (2005) 134-140
7. Suniara R.K., Jenkinson E.J., and Owen J.J. An essential role for thymic mesenchyme in early T cell development. J. Exp. Med. 191 (2000) 1051-1056
8. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., and Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2000) 3838-3843
9. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
10. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., and Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171 (2003) 3426-3434
11. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., and Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
12. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5 (2003) 485-489
13. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., and Deans R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 (2002) 42-48
14. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57 (2003) 11-20
15. Le Blanc K., Gotherstrom C., and Rasmusson I. Mesenchymal stem cell inhibit the expression of CD25 (IL-2 receptor) and CD38 on pythohaemagglutinin activated lymphocyes. Scand. J. Immunol. (2004) 307-315
16. Margaret Eg., Basabi M., Emese S., and Omer N.K. Human mesenchymal stem cells require monocytes mediated activation to suppress alloreactive T cells. Exp. Hematol. (2005) 928-934
17. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
18. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
19. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., Daudt L., Ibatici A., Piaggio G., Pozzi S., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
20. Glennie S., Soeiro I., Dyson P.J., Lam E.W.F., and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105 (2005) 2821-2827
21. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., Santarlasci V., Mazzinghi B., Pizzolo G., Vinante F., et al. Role for IFN-{gamma} in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 2005-2008
22. Zvaifler N.J., Marinova-Mutafchieva L., Adams G., Edwards C.J., Moss J., Burger J.A., and Maini R.N. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2 (2002) 477-488
23. Majumdar M.K., Keane-Moore M., Buyaner D., Hardy W.B., Moorman M.A., McIntosh K.R., and Mosca J.D. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10 (2003) 228-241
24. Sancho D., Gomez M., and Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26 (2005) 136-140
25. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398
26. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5 (1999) 309-313
27. Seung Tae L., Joon Ho J., June-Won C., Jin Seok K., Ho-Young M., Jee Sook H., Yun Woong K., and You S. Treatment of hight risk acute myelogenous leukaemia by myeloblative chemotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cell from a related donor with one fully mismatched human leucocytes antigen haplotype. Br. J. Haematol. (2002) 1128-1131
28. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
29. Gottschalk S., Heslop H.E., and Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk. Lymphoma 46 (2005) 1-10
30. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., and Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6 (2000) 1018-1023